Abstract Number: 0401 • ACR Convergence 2021
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…Abstract Number: 0763 • ACR Convergence 2021
What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset
Background/Purpose: Parent- and child-reported outcomes (PCROs) reflect the parent and child perception of rheumatic disease course and effectiveness of therapeutic interventions. Among PCROs for the…Abstract Number: 0869 • ACR Convergence 2021
Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
Background/Purpose: Frailty is a novel risk factor for adverse health outcomes in systemic lupus erythematosus (SLE). Multiple definitions of frailty, including the Fried definition (FD),…Abstract Number: 1223 • ACR Convergence 2021
A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort
Background/Purpose: Baricitinib (BARI) is a JAK1/2 inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) and the treatment of…Abstract Number: 1380 • ACR Convergence 2021
Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study
Background/Purpose: Calcinosis cutis (CC) can commonly affect patients with systemic sclerosis (SSc), which is often painful, resulting in functional impairment and morbidity. A radiographic scoring…Abstract Number: 1672 • ACR Convergence 2021
Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…Abstract Number: 0145 • ACR Convergence 2021
Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care
Background/Purpose: Patient-reported outcomes (PROs) are surveys completed by patients to provide measurements of health, quality of life, symptoms, and functional status. PROs are useful for…Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…Abstract Number: 0743 • ACR Convergence 2021
Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
Background/Purpose: People living with idiopathic inflammatory myositis (IIM) suffer impairments in health-related quality of life (HRQL), especially in the domains of pain interference, fatigue, and…Abstract Number: 0766 • ACR Convergence 2021
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…Abstract Number: 0909 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Background/Purpose: Current studies suggest that the phenotype of spondyloarthritis differs between genders and that this may influence the subsequent diagnostic approach and therapeutic decisions1. The…Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…Abstract Number: 1418 • ACR Convergence 2021
Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can…Abstract Number: 1673 • ACR Convergence 2021
Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 43
- Next Page »